Observational studyFrontiers in cellular and infection microbiology2026
Analysis of the efficacy and safety of intravenous injection combined with nebulized inhalation of polymyxin E sodium methanesulfonate in the treatment of carbapenem resistant gram-negative bacterial infections in the lungs.
Observational study in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Gram-negative (CR-GN) pneumonia remains a major therapeutic challenge due to limited effective treatment options and high morbidity. Polymyxin E sodium methanesulfonate (colistin), despite concerns of nephrotoxicity, continues to serve as a last-resort agent. The adjunctive use of nebulized polymyxin may enhance local drug delivery and improve outcomes. Objective: To evaluate the clinical efficacy, microbiological clearance, radiological response, and safety of combined intravenous and nebulized polymyxin E in patients with CR-GN pneumonia, and to identify early predictors of treatment response. Methods: This retrospective, single-center observational study included 120 adult patients with microbiologically confirmed CR-GN pneumonia treated between January 2022 and December 2024. All patients received intravenous polymyxin E along with nebulized polymyxin E (50 mg twice daily). Clinical parameters, laboratory markers, radiological findings, and adverse events were assessed at baseline (Day 0), Day 5, and Day 10-14. Multivariate logistic regression and receiver operating characteristic (ROC) curve analysis were performed to identify predictors of poor outcomes. Results: Significant improvements were observed across clinical parameters, including reduction in temperature (38.6 °C to 36.9 °C), respiratory rate, and improvement in oxygenation (SpO Conclusion: Combined intravenous and nebulized polymyxin E therapy was associated with favorable clinical and microbiological outcomes in patients with CR-GN pneumonia, with an acceptable safety profile. Early biomarkers such as procalcitonin, CRP, and oxygenation indices may help guide risk stratification and optimize treatment strategies in critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.